Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Leo Miller

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Since tanking in early August, shares of Eli Lilly and Company (NYSE: LLY) have roared back with a vengeance. The world’s most valuable healthcare stock plummeted around 14% on Aug. 7 after releasing somewhat disappointing data on its developmental oral GLP-1 drug, orforglipron. Eli Lilly shares have surged around 40% from that August dip.

Aiding the stock’s rise was Lilly’s Q3 2025 earnings report, released on Oct. 30. Shares rose around 10% over the three following trading days. Below, we’ll break down Eli Lilly’s latest earnings and gain an updated outlook on the stock. Overall, how should investors view the short- and long-term potential of Eli Lilly shares? 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.